ESMO: DS-8201 Advances in Second-Line Treatment for HER2-Positive Gastric Cancer
On September 10, 2022, updated data from the open-label, multicenter Phase II DESTINY-Gastric02 study were presented at the ESMO conference, showing that DS-8201 demonstrated sustained clinical benefits and acceptable safety in patients with locally advanced or metastatic HER2-positive gastric cancer or gastroesophageal junction (GEJ) cancer who had previously received trastuzumab-based therapy. The study included 79 … Read more